


Amendments to the Claims

1. (Currently Amended) A compound of formula I:



(I)

wherein:

Ar^1 is a cyclic group optionally substituted with one to five groups selected from $\text{C}_1\text{-}\text{C}_8$ alkyl, $\text{C}_2\text{-}\text{C}_8$ alkenyl, $\text{C}_2\text{-}\text{C}_8$ alkynyl, hydroxy, $\text{C}_1\text{-}\text{C}_8$ alkoxy, $\text{C}_1\text{-}\text{C}_8$ alkylaryl, phenyl, aryl, -O-aryl, heteroaryl, cycloalkyl, $\text{C}_1\text{-}\text{C}_8$ alkylcycloalkyl, cyano, $-(\text{CH}_2)_n\text{NR}^6\text{R}^6$, $\text{C}_1\text{-}\text{C}_8$ haloalkyl, $\text{C}_1\text{-}\text{C}_8$ haloalkoxy, halo, $(\text{CH}_2)_n\text{COR}^6$, $(\text{CH}_2)_n\text{NR}^5\text{SO}_2\text{R}^6$, $-(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$, heterocyclic, and $\text{C}_1\text{-}\text{C}_8$ alkylheterocyclic; wherein the cycloalkyl, phenyl, aryl, and heterocyclic groups are each optionally substituted with one to three groups independently selected from hydroxy, $\text{C}_1\text{-}\text{C}_8$ alkoxyalkyl, $\text{C}_1\text{-}\text{C}_8$ haloalkoxy, $\text{C}_1\text{-}\text{C}_8$ alkyl, halo, $\text{C}_1\text{-}\text{C}_8$ haloalkyl, nitro, cyano, amino, carboxamido, phenyl, aryl, alkylheterocyclic, heterocyclic, and oxo;

L^1 is a bond, $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{SCH}_2-$, $-\text{OCH}_2-$, $-\text{CH}_2\text{SCH}_2-$, $-\text{CH}_2\text{OCH}_2-$, $-\text{OCH}_2\text{CH}_2\text{SCH}_2-$, or a divalent linker represented by the formula $\text{X}_2-(\text{CR}^3\text{R}^4)_m\text{-X}_3$ where X_2 is attached to Ar^1 and X_3 is attached to Ar^2 wherein R^3 and R^4 are independently selected from a bond, hydrogen, $\text{C}_1\text{-}\text{C}_8$ alkyl, $\text{C}_2\text{-}\text{C}_8$ alkylene, $\text{C}_2\text{-}\text{C}_8$ alkynyl, phenyl, aryl, $\text{C}_1\text{-}\text{C}_8$ alkylaryl; wherein the alkyl, alkenyl, phenyl, and aryl groups are optionally substituted with one to five substituents independently selected from oxo, nitro, cyano, $\text{C}_1\text{-}\text{C}_8$ alkyl, aryl, halo, hydroxy, $\text{C}_1\text{-}\text{C}_8$ alkoxy, $\text{C}_1\text{-}\text{C}_8$ haloalkyl, $(\text{CH}_2)_n\text{C}(\text{O})\text{R}^6$, and $(\text{CH}_2)_n\text{CONR}^6\text{R}^6$;

X_2 is independently oxygen, $-\text{CH}$, $-\text{CONH}(\text{CR}^3\text{R}^4)_m$, $-\text{NHCO}(\text{CR}^3\text{R}^4)_m$, $-(\text{CR}^3\text{R}^4)_m$, $-\text{CHR}^6$, $-\text{NR}^5$, S , SO , SO_2 , $-\text{O}(\text{CR}^3\text{R}^4)_m$, or $-\text{S}(\text{CR}^3\text{R}^4)_m$;

X_3 is independently oxygen, $-\text{C}$, $-\text{CH}$, $-\text{CHR}^6$, $-(\text{CR}^3\text{R}^4)_m$, $-\text{NR}^5$, S , SO , or SO_2 ;

Ar^2 is a 5-member monocyclic heterocyclic aromatic group or positional isomer thereof, having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and wherein Ar^2 is optionally substituted with one to three substituents independently selected from $\text{C}_1\text{-}\text{C}_8$ alkyl, $\text{C}_2\text{-}\text{C}_8$ alkenyl, $\text{C}_2\text{-}\text{C}_8$ alkynyl, hydroxy, $\text{C}_1\text{-}\text{C}_8$ alkoxy, $\text{C}_1\text{-}\text{C}_8$ alkylaryl, phenyl, aryl, $\text{C}_3\text{-}\text{C}_8$ cycloalkyl, $\text{C}_1\text{-}\text{C}_8$ alkylcycloalkyl, cyano, $\text{C}_1\text{-}\text{C}_8$ haloalkyl, halo,

$(CH_2)_nC(O)R^6$, $(CH_2)_nC(O)OR^6$, $(CH_2)_nNR^5SO_2R^6$, $(CH_2)_nC(O)NR^6R^6$, and C_1-C_8 alkylheterocyclic;

Ar^3 is an optionally substituted bicyclic aromatic or non-aromatic group;

L^2 is $-CH_2-$, $-CH_2CH_2-$ or a divalent linker represented by the formula $X_4-(CR^3R^4)_m-X_5$; wherein X_4 is selected from the group consisting of C, -CH, CHR^6 , -CO, O, - NR^5 , -NC(O)-, -NC(S), -C(O) NR^5 -, - $NR^6'C(O)NR^6$, - $NR^6'C(S)NR^6$, - SO_2NR^7 , - $NRSO_2R^7$, and - $NR^6'C(NR^5)NR^6$;

X_5 is selected from the group consisting of O, - CH_2 , -CH, - $O(CR^3R^4)_m$, $NR^3(CR^3R^4)_m$, SO, SO_2 , S, and SCH_2 ; wherein the group $X_4-(CR^3R^4)_m-X_5$ imparts stability to the compound of formula (1) and may be a saturated or unsaturated chain or divalent linker;

R^1 and R^2 are independently hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_3-C_8 cycloalkyl, C_1-C_8 alkylaryl, -C(O) C_1-C_8 alkyl, -C(O)OC $_1-C_8$ alkyl, C_1-C_8 alkylcycloalkyl, $(CH_2)_nC(O)OR^5$, $(CH_2)_nC(O)R^5$, $(CH_2)_nC(O)NR^6R^6$, and $(CH_2)_nNSO_2R^5$; wherein each of the alkyl, alkenyl, aryl are each optionally substituted with one to five groups independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, phenyl, and alkylaryl; and wherein R^1 and R^2 may combine together, and with the nitrogen atom to which they are attached or with 0, 1, 2 or 3 atoms adjacent to the nitrogen atom to form a nitrogen containing heterocycle which may have 1, or 2 substituents independently selected from C_1-C_8 alkyl, C_2-C_8 alkenyl, C_3-C_8 cycloalkyl, C_1-C_8 alkylaryl, -C(O) C_1-C_8 alkyl, -C(O)OC $_1-C_8$ alkyl, C_1-C_8 alkylcycloalkyl, oxo, halo amino, and $(CH_2)_nC(O)NR^6R^6$;

R^5 is hydrogen, CN, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_5-C_8 alkylaryl, $(CH_2)_nNSO_2C_1-C_8$ alkyl, $(CH_2)_nNSO_2$ phenyl, $(CH_2)_nNSO_2$ aryl, -C(O) C_1-C_8 alkyl, or -C(O)OC $_1-C_8$ alkyl; and

R^6 and R^6' are each independently hydrogen, C_1-C_8 alkyl, phenyl, aryl, C_1-C_8 alkylaryl, C_1-C_8 alkylcycloalkyl, or C_3-C_8 cycloalkyl;

R^7 is hydrogen, C_1-C_8 alkyl, phenyl, aryl, C_1-C_8 alkylaryl, or C_3-C_8 cycloalkyl, and wherein m is an integer from 1 to 8; and n is an integer from 0 to 8;

or a pharmaceutically acceptable salt, solvate, racemate, or enantiomer diastereomer or mixture of diastereomers thereof.

2. (Original) A compound according to Claim 1 wherein the group Ar^1 is selected from the group consisting of: phenyl, benzothiophene, benzofuran, or naphthyl.

3. (Original) A compound according to Claim 1 wherein the group L¹ is a linker selected from the group consisting of: -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -SCH₂-, -OCH₂-, -CH₂SCH₂-, -CH₂OCH₂-, or -OCH₂CH₂SCH₂-.

4. (Original) A compound according to Claim 1 wherein Ar³ is an aromatic group selected from the group consisting of: indole, naphthyl, tetrahydronaphthyl, isoindolinone, isoquinolone, benzothiophene, or benzofuran.

5. (Original) A compound of Claim 1 wherein Ar² is a 4 or 5 member aromatic group selected from the group consisting of: oxazole, oxadiazole, or furan.

6. (Original) A compound according to Claim 1 wherein the linker (L²) is: -CH₂-, -CH₂CH₂-, or -CH₂CH₂CH₂-.

7. (Original) A compound according to Claim 1 wherein R¹ and R² combine with the nitrogen atom to form piperidinyl, pyrrolidinyl, azepine, or azetidinyl.

8. (Original) A compound according to Claim 1 wherein R¹ and R² are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, methylcyclopentane, methylcyclohexane, phenyl, benzyl, cyclopentyl, cyclohexyl, methylcyclopropane and methylcyclobutane.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Original) A compound according to Claim 1 wherein at least one of L¹ and L² has a chain length of 3 to 5 atoms.

13. (Currently Amended) A compound selected from the group consisting of: Dimethyl-{6-[5-(2-phenoxy-ethylsulfanyl)methyl]-[1,3,4]oxadiazol-2-yl]-benzofuran-2-

ylmethyl}-amine oxalate,

Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-benzofuran-2-ylmethyl}-amine oxalate,

{1-Methanesulfonyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,

Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,

{1-Methanesulfonyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,

Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine,

Dimethyl-{1-methyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,

Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,

Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine maleate,

Dimethyl-{1-methyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,

Dimethyl-{4-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-1-yl}-amine,

Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-amine,

2-(2-Phenoxy-ethylsulfanylmethyl)-5-(6-pyrrolidin-1-ylmethyl-naphthalen-2-yl)-[1,3,4]oxadiazole maleate,




1-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-piperidine,

2-(2-piperidinoethyl)-5-{2-[((2-phenoxyethyl)thio)methyl]-1,3,4-oxadiazol-5-yl}isoindolin-1-one,


~~2-[(2-Phenoxyethyl)thio]methyl 5-[3-hydroxymethyl-4-[(2-piperidinoethyl)amino]carbonyl]phenyl] 1,3,4-oxadiazole;~~

~~2-(2-piperidinoethyl)-5-[2-[(2-phenoxyethyl)thio)methyl]-1,3,4-oxadiazol-5-yl]isoindolin-1-one, and pharmaceutically acceptable salt, solvate, enantiomer, prodrug, diastereomer or mixture thereof.~~

14. (Original) A compound selected from the group consisting of:



, and



or pharmaceutically acceptable salt, racemate, solvate, enantioner or diastereomer or mixture of diastereomers thereof.

15. (Cancelled)

16. (Currently Amended) A method of treating Type II Diabetes comprising administering to a patient in need thereof a compound of ~~any one of Claims 1-14~~Claim 1.

17. (Currently Amended) A method of treating obesity and Related Diseases comprising administering to a patient in need thereof a compound of ~~any one of Claims 1-14~~Claim 1.

18. (Cancelled)

19. (Currently Amended) A pharmaceutical formulation comprising a compound of ~~any one of Claims 1-14~~Claim 1 and a pharmaceutical carrier.

20. (Cancelled)